Core Viewpoint - Aimeike has completed its first new cosmetic ingredient filing, "Glycyrrhizic Chalcone A," derived from the traditional Chinese plant licorice, marking a significant step in its strategic expansion into the cosmetics sector [2][3][4]. Group 1: Business Development - Aimeike is actively expanding its cosmetics business, leveraging its technological advantages accumulated in the medical aesthetics field to drive innovation [4][8]. - The company reported a revenue of 1.299 billion yuan in the first half of 2025, a year-on-year decline of 21.6%, and a net profit of 789 million yuan, down 29.6%, indicating pressure on its core products [6]. - Aimeike has initiated a multi-line transformation strategy, including product diversification and pipeline expansion, with new products like "Gakola" and ongoing clinical trials for other products [6][8]. Group 2: Market Context - The cosmetic ingredient market is experiencing intense competition, with a 77.8% year-on-year increase in new ingredient filings in the first half of the year, highlighting the growing interest in this sector [11]. - Major players like Proya and Beautylife have also completed new ingredient filings, indicating a trend among domestic beauty giants to secure upstream raw material capabilities [11]. Group 3: Strategic Challenges - Aimeike faces significant challenges, including a lack of experience in managing cosmetic raw material supply chains and the need for time to transition from filing to commercialization [12]. - The company is also contending with established competitors who have first-mover advantages and the potential for regulatory hurdles during the three-year monitoring period following the new ingredient filing [12].
爱美客高调布局化妆品原料端,成色几何?